TY - JOUR T1 - Lung cancer in women: What are particularities? JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P1061 AU - Rihab Bay AU - Soumaya Ben Saad AU - Hafaoua Daghfous AU - Hala Cherif AU - Fatma Tritar Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P1061.abstract N2 - Introduction:Lung cancer (LC) is becoming more and more common in women where it presents significant differences at both clinical and therapeutic levels.Objectives:Evaluate clinical, therapeutic and prognostic features of LC in female patients.Methods:Our study include164 patients witch were treated for LC between 2006 and 2013: 29 women (G1) and 135 men (G2). These two groups (G1 and G2) were compared (age, past history, interventions, TNM stage and long term survival).Results:Mean age of patients was 62 years in the 2 groups. Smoking is significantly higher in G2 (97% vs 18,5%; p<0.05). Women were exposed to environmental tobacco smoke in 48 % of cases and to woodsmoke (Tabouna) in 13% of cases. Comorbidity was present in 32 % of the population. Respiratory signs and superior vena cava syndrome are less frequent in women. Performans status (PS) was well in 66% of women and 44% of men (p<0.05). CT guided biopsy was used in 27 % of cases in G2 and 7% of cases in G1 (p<0.05). LC was metastatic in 66% of cases without any difference between the 2 groups. Squamous cell carcinoma was more frequent in G2 (28,3% vs 6,9%; p=0,016). Chemotherapy was indicated in 72,4% of cases in G1 and 72,6% of cases in G2. Tumor progression after chemotherapy are more frequent in G2 than G1 (72% vs 64%; p=0,06). Mediane survival was 9 months in G1 and 6 in G2 months (p<0.05). .Conclusion:Because less comorbidities, better PS and better chemosensitivity female patients with LC have better prognosis. ER -